HER2 signaling pathway and trastuzumab cardiotoxicity

Future Oncology

Volumn 9, Issue 2, 2013, Pages 179-181

  Criscitiello, Carmen ^a   Curigliano, Giuseppe ^a  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

breast cancer; cardiac toxicity; trastuzumab

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; TRASTUZUMAB; TROPONIN;

ARTICLE; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RECURRENCE; CARDIOLOGIST; CARDIOTOXICITY; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR RISK; COMORBIDITY; CONGESTIVE HEART FAILURE; DRUG EFFICACY; DRUG EXPOSURE; DRUG INDUCED DISEASE; DRUG SAFETY; DRUG WITHDRAWAL; ELECTROCARDIOGRAM; FOLLOW UP; HEART FUNCTION; HEART INJURY; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; OUTCOME ASSESSMENT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; RECURRENCE RISK; RISK ASSESSMENT; SIGNAL TRANSDUCTION;

EID: 84874066768     PISSN: 14796694     EISSN: 17448301     Source Type: Journal    
DOI: 10.2217/fon.12.193     Document Type: Article

References (15)

1. Romond EH, Perez EA, Bryant J et al. Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1673-1684 (2005).
2. Smith I, Procter M, Gelber RD et al. 2year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: A randomised controlled trial. Lancet 369(9555), 29-36 (2007).
3. Piccart-Gebhart MJ, Procter M, Leyland-Jones B et al. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer. N. Engl. J. Med. 353(16), 1659-1672 (2005).
4. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf. 31(6), 459-467 (2008).
5. Mackey JR, Clemons M, Cote MA et al. Cardiac management during adjuvant trastuzumab therapy: recommendations of the Canadian Trastuzumab Working Group. Curr. Oncol. 15(1), 24-35 (2008).
6. de Azambuja E, Bedard PL, Suter T, Piccart-Gebhart M. Cardiac toxicity with anti-HER-2 therapies: what have we learned so far? Target Oncol. 4(2), 77-88 (2009).
7. Perez EA, Suman VJ, Davidson NE et al. Cardiac safety analysis of doxorubicin and cyclophosphamide followed by paclitaxel with or without trastuzumab in the North Central Cancer Treatment Group N9831 adjuvant breast cancer trial. J. Clin. Oncol. 26(8), 1231-1238 (2008).
8. Procter M, Suter TM, de Azambuja E et al. Longer-term assessment of trastuzumab-related cardiac adverse events in the Herceptin Adjuvant (HERA) trial. J. Clin. Oncol. 28(21), 3422-3428 (2010).
9. Gianni L, Dafni U, Gelber RD et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: A 4year follow-up of a randomised controlled trial. Lancet Oncol. 12(3), 236-244 (2011).
10. Slamon D, Eiermann W, Robert N et al. Adjuvant trastuzumab in HER2-positive breast cancer. N. Engl. J. Med. 365(14), 1273-1283 (2011).
11. Romond EH, Jeong JH, Rastogi P et al. Seven-year follow-up assessment of cardiac function in NSABP B31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab as adjuvant therapy for patients with nodepositive, human epidermal growth factor receptor 2-positive breast cancer. J. Clin. Oncol. 30(31), 3792-3799 (2012).
12. Bowles EJ, Wellman R, Feigelson HS et al. Risk of heart failure in breast cancer patients after anthracycline and trastuzumab treatment: A retrospective cohort study. J. Natl Cancer Inst. 104(17), 1293-1305 (2012).
13. Wagner EH, Greene SM, Hart G et al. Building a research consortium of large health systems: the Cancer Research Network. J. Natl Cancer Inst. Monogr. 35, 3-11 (2005).
14. Cardinale D, Sandri MT. Role of biomarkers in chemotherapy-induced cardiotoxicity. Prog. Cardiovasc. Dis. 53, 121-129 (2010).
15. Cardinale D, Colombo A, Torrisi R et al. Trastuzumab-induced cardiotoxicity: clinical and prognostic implications of troponin I evaluation. J. Clin. Oncol. 28, 3910-3916 (2010).